Reuters logo
BRIEF-Aldeyra Therapeutics receives orphan drug designation from FDA
April 20, 2017 / 12:07 PM / 6 months ago

BRIEF-Aldeyra Therapeutics receives orphan drug designation from FDA

April 20 (Reuters) - Aldeyra Therapeutics Inc:

* Aldeyra Therapeutics Inc receives orphan drug designation from the U.S. Food And Drug Administration for ADX-102 in sjögren-larsson syndrome

* Aldeyra Therapeutics Inc- FDA granted Aldeyra’s novel compound ADX-102 orphan drug designation for treatment of congenital ichthyosis

* Aldeyra Therapeutics Inc- pivotal phase 3 study is expected to begin later this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below